1
|
Farivar N, Khazamipour N, Roberts ME, Nelepcu I, Marzban M, Moeen A, Oo HZ, Nakouzi NA, Dolleris C, Black PC, Daugaard M. Pulsed Photothermal Therapy of Solid Tumors as a Precondition for Immunotherapy. Small 2024:e2309495. [PMID: 38511548 DOI: 10.1002/smll.202309495] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 03/07/2024] [Indexed: 03/22/2024]
Abstract
Photothermal therapy (PTT) refers to the use of plasmonic nanoparticles to convert electromagnetic radiation in the near infrared region to heat and kill tumor cells. Continuous wave lasers have been used clinically to induce PTT, but the treatment is associated with heat-induced tissue damage that limits usability. Here, the engineering and validation of a novel long-pulsed laser device able to induce selective and localized mild hyperthermia in tumors while reducing the heat affected zone and unwanted damage to surrounding tissue are reported. Long-pulsed PTT induces acute necrotic cell death in heat affected areas and the release of tumor associated antigens. This antigen release triggers maturation and stimulation of CD80/CD86 in dendritic cells in vivo that primes a cytotoxic T cell response. Accordingly, long-pulsed PTT enhances the therapeutic effects of immune checkpoint inhibition and increases survival of mice with bladder cancer. Combined, the data promote long-pulsed PTT as a safe and effective strategy for enhancing therapeutic responses to immune checkpoint inhibitors while minimizing unwanted tissue damage.
Collapse
Affiliation(s)
- Negin Farivar
- Department of Experimental Medicine, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| | - Nastaran Khazamipour
- Department of Experimental Medicine, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| | - Morgan E Roberts
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| | - Irina Nelepcu
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| | - Mona Marzban
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| | - Alireza Moeen
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| | - Htoo Zarni Oo
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| | - Nader Al Nakouzi
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| | - Casper Dolleris
- Dolleris Scientific Corp., 2327 Collingwood Street, Vancouver, BC, V6R 3L2, Canada
| | - Peter C Black
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| | - Mads Daugaard
- Department of Experimental Medicine, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
- Vancouver Prostate Centre, Vancouver, BC, V6H 3Z6, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, V5Z 1M9, Canada
| |
Collapse
|
2
|
Wang CK, Nelepcu I, Hui D, Oo HZ, Truong S, Zhao S, Tahiry Z, Esfandnia S, Ghaidi F, Adomat H, Dagil R, Gustavsson T, Choudhary S, Salanti A, Sorensen PH, Al Nakouzi N, Daugaard M. Internalization and trafficking of CSPG-bound recombinant VAR2CSA lectins in cancer cells. Sci Rep 2022; 12:3075. [PMID: 35197518 PMCID: PMC8866492 DOI: 10.1038/s41598-022-07025-6] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2021] [Accepted: 02/04/2022] [Indexed: 02/07/2023] Open
Abstract
Proteoglycans are proteins that are modified with glycosaminoglycan chains. Chondroitin sulfate proteoglycans (CSPGs) are currently being exploited as targets for drug-delivery in various cancer indications, however basic knowledge on how CSPGs are internalized in tumor cells is lacking. In this study we took advantage of a recombinant CSPG-binding lectin VAR2CSA (rVAR2) to track internalization and cell fate of CSPGs in tumor cells. We found that rVAR2 is internalized into cancer cells via multiple internalization mechanisms after initial docking on cell surface CSPGs. Regardless of the internalization pathway used, CSPG-bound rVAR2 was trafficked to the early endosomes in an energy-dependent manner but not further transported to the lysosomal compartment. Instead, internalized CSPG-bound rVAR2 proteins were secreted with exosomes to the extracellular environment in a strictly chondroitin sulfate-dependent manner. In summary, our work describes the cell fate of rVAR2 proteins in tumor cells after initial binding to CSPGs, which can be further used to inform development of rVAR2-drug conjugates and other therapeutics targeting CSPGs.
Collapse
Affiliation(s)
- Chris Kedong Wang
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.,Vancouver Prostate Centre, Vancouver, BC, Canada
| | - Irina Nelepcu
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.,Vancouver Prostate Centre, Vancouver, BC, Canada
| | - Desmond Hui
- Vancouver Prostate Centre, Vancouver, BC, Canada
| | - Htoo Zarni Oo
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.,Vancouver Prostate Centre, Vancouver, BC, Canada
| | - Sarah Truong
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.,Vancouver Prostate Centre, Vancouver, BC, Canada
| | - Sarah Zhao
- Vancouver Prostate Centre, Vancouver, BC, Canada
| | - Zakir Tahiry
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada.,Vancouver Prostate Centre, Vancouver, BC, Canada
| | | | | | - Hans Adomat
- Vancouver Prostate Centre, Vancouver, BC, Canada
| | - Robert Dagil
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark.,VAR2 Pharmaceuticals, Copenhagen, Denmark
| | - Tobias Gustavsson
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark.,VAR2 Pharmaceuticals, Copenhagen, Denmark
| | - Swati Choudhary
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark.,VAR2 Pharmaceuticals, Copenhagen, Denmark
| | - Ali Salanti
- Centre for Medical Parasitology at Department for Immunology and Microbiology, Faculty of Health and Medical Sciences, University of Copenhagen and Department of Infectious Disease, Copenhagen University Hospital, Copenhagen, Denmark.,VAR2 Pharmaceuticals, Copenhagen, Denmark
| | - Poul H Sorensen
- Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC, Canada
| | - Nader Al Nakouzi
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. .,Vancouver Prostate Centre, Vancouver, BC, Canada. .,VAR2 Pharmaceuticals, Copenhagen, Denmark.
| | - Mads Daugaard
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada. .,Vancouver Prostate Centre, Vancouver, BC, Canada. .,VAR2 Pharmaceuticals, Copenhagen, Denmark.
| |
Collapse
|
3
|
Müller I, Strozyk E, Schindler S, Beissert S, Oo HZ, Sauter T, Lucarelli P, Raeth S, Hausser A, Al Nakouzi N, Fazli L, Gleave ME, Liu H, Simon HU, Walczak H, Green DR, Bartek J, Daugaard M, Kulms D. Cancer Cells Employ Nuclear Caspase-8 to Overcome the p53-Dependent G2/M Checkpoint through Cleavage of USP28. Mol Cell 2020; 77:970-984.e7. [PMID: 31982308 PMCID: PMC7060810 DOI: 10.1016/j.molcel.2019.12.023] [Citation(s) in RCA: 42] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Revised: 08/28/2019] [Accepted: 12/20/2019] [Indexed: 02/08/2023]
Abstract
Cytosolic caspase-8 is a mediator of death receptor signaling. While caspase-8 expression is lost in some tumors, it is increased in others, indicating a conditional pro-survival function of caspase-8 in cancer. Here, we show that tumor cells employ DNA-damage-induced nuclear caspase-8 to override the p53-dependent G2/M cell-cycle checkpoint. Caspase-8 is upregulated and localized to the nucleus in multiple human cancers, correlating with treatment resistance and poor clinical outcome. Depletion of caspase-8 causes G2/M arrest, stabilization of p53, and induction of p53-dependent intrinsic apoptosis in tumor cells. In the nucleus, caspase-8 cleaves and inactivates the ubiquitin-specific peptidase 28 (USP28), preventing USP28 from de-ubiquitinating and stabilizing wild-type p53. This results in de facto p53 protein loss, switching cell fate from apoptosis toward mitosis. In summary, our work identifies a non-canonical role of caspase-8 exploited by cancer cells to override the p53-dependent G2/M cell-cycle checkpoint.
Collapse
Affiliation(s)
- Ines Müller
- Experimental Dermatology, Department of Dermatology, TU-Dresden, Dresden 01307, Germany; Center for Regenerative Therapies Dresden, TU-Dresden, Dresden 01307, Germany
| | - Elwira Strozyk
- Experimental Dermatology, Department of Dermatology, TU-Dresden, Dresden 01307, Germany; Center for Regenerative Therapies Dresden, TU-Dresden, Dresden 01307, Germany
| | - Sebastian Schindler
- Experimental Dermatology, Department of Dermatology, TU-Dresden, Dresden 01307, Germany; Center for Regenerative Therapies Dresden, TU-Dresden, Dresden 01307, Germany
| | - Stefan Beissert
- Experimental Dermatology, Department of Dermatology, TU-Dresden, Dresden 01307, Germany
| | - Htoo Zarni Oo
- Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
| | - Thomas Sauter
- Systems Biology, Life Science Research Unit, University of Luxembourg, 1511 Luxembourg, Luxembourg
| | - Philippe Lucarelli
- Systems Biology, Life Science Research Unit, University of Luxembourg, 1511 Luxembourg, Luxembourg
| | - Sebastian Raeth
- Institute of Cell Biology and Immunology and Stuttgart Research Centre Systems Biology, University of Stuttgart, Stuttgart 70569, Germany
| | - Angelika Hausser
- Institute of Cell Biology and Immunology and Stuttgart Research Centre Systems Biology, University of Stuttgart, Stuttgart 70569, Germany
| | - Nader Al Nakouzi
- Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
| | - Ladan Fazli
- Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
| | - Martin E Gleave
- Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
| | - He Liu
- Institute of Pharmacology, University of Bern, Bern 3010, Switzerland
| | - Hans-Uwe Simon
- Institute of Pharmacology, University of Bern, Bern 3010, Switzerland
| | - Henning Walczak
- Centre for Cell Death, Cancer and Inflammation, UCL Cancer Institute, University College London, London WC1E 6DD, UK
| | - Douglas R Green
- Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA
| | - Jiri Bartek
- Danish Cancer Society Research Center, Copenhagen 2100, Denmark; Division of Genome Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institute, Stockholm 171 77, Sweden
| | - Mads Daugaard
- Department of Urologic Sciences, Faculty of Medicine, University of British Columbia, Vancouver, BC V5Z 1M9, Canada; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
| | - Dagmar Kulms
- Experimental Dermatology, Department of Dermatology, TU-Dresden, Dresden 01307, Germany; Center for Regenerative Therapies Dresden, TU-Dresden, Dresden 01307, Germany.
| |
Collapse
|
4
|
Nappi L, Aguda AH, Nakouzi NA, Lelj-Garolla B, Beraldi E, Lallous N, Thi M, Moore S, Fazli L, Battsogt D, Stief S, Ban F, Nguyen NT, Saxena N, Dueva E, Zhang F, Yamazaki T, Zoubeidi A, Cherkasov A, Brayer GD, Gleave M. Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models. J Clin Invest 2020; 130:699-714. [PMID: 31845908 PMCID: PMC6994194 DOI: 10.1172/jci130819] [Citation(s) in RCA: 32] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/07/2019] [Accepted: 10/22/2019] [Indexed: 01/07/2023] Open
Abstract
HSP27 is highly expressed in, and supports oncogene addiction of, many cancers. HSP27 phosphorylation is a limiting step for activation of this protein and a target for inhibition, but its highly disordered structure challenges rational structure-guided drug discovery. We performed multistep biochemical, structural, and computational experiments to define a spherical 24-monomer complex composed of 12 HSP27 dimers with a phosphorylation pocket flanked by serine residues between their N-terminal domains. Ivermectin directly binds this pocket to inhibit MAPKAP2-mediated HSP27 phosphorylation and depolymerization, thereby blocking HSP27-regulated survival signaling and client-oncoprotein interactions. Ivermectin potentiated activity of anti-androgen receptor and anti-EGFR drugs in prostate and EGFR/HER2-driven tumor models, respectively, identifying a repurposing approach for cotargeting stress-adaptive responses to overcome resistance to inhibitors of oncogenic pathway signaling.
Collapse
Affiliation(s)
- Lucia Nappi
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | | | | | | | - Eliana Beraldi
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Nada Lallous
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Marisa Thi
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Susan Moore
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Ladan Fazli
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | | | - Sophie Stief
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Fuqiang Ban
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Nham T. Nguyen
- Department of Biochemistry and Molecular Biology, Life Sciences Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Neetu Saxena
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Evgenia Dueva
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Fan Zhang
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | | | - Amina Zoubeidi
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Artem Cherkasov
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| | - Gary D. Brayer
- Department of Biochemistry and Molecular Biology, Life Sciences Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Martin Gleave
- Department of Urologic Sciences, Vancouver Prostate Centre, and
| |
Collapse
|
5
|
Garrido MF, Martin NJP, Bertrand M, Gaudin C, Commo F, El Kalaany N, Al Nakouzi N, Fazli L, Del Nery E, Camonis J, Perez F, Lerondel S, Le Pape A, Compagno D, Gleave M, Loriot Y, Désaubry L, Vagner S, Fizazi K, Chauchereau A. Regulation of eIF4F Translation Initiation Complex by the Peptidyl Prolyl Isomerase FKBP7 in Taxane-resistant Prostate Cancer. Clin Cancer Res 2018; 25:710-723. [PMID: 30322877 DOI: 10.1158/1078-0432.ccr-18-0704] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/01/2018] [Revised: 07/29/2018] [Accepted: 10/10/2018] [Indexed: 11/16/2022]
Abstract
PURPOSE Targeted therapies that use the signaling pathways involved in prostate cancer are required to overcome chemoresistance and improve treatment outcomes for men. Molecular chaperones play a key role in the regulation of protein homeostasis and are potential targets for overcoming chemoresistance.Experimental Design: We established 4 chemoresistant prostate cancer cell lines and used image-based high-content siRNA functional screening, based on gene-expression signature, to explore mechanisms of chemoresistance and identify new potential targets with potential roles in taxane resistance. The functional role of a new target was assessed by in vitro and in vivo silencing, and mass spectrometry analysis was used to identify its downstream effectors. RESULTS We identified FKBP7, a prolyl-peptidyl isomerase overexpressed in docetaxel-resistant and in cabazitaxel-resistant prostate cancer cells. This is the first study to characterize the function of human FKBP7 and explore its role in cancer. We discovered that FKBP7 was upregulated in human prostate cancers and its expression correlated with the recurrence observed in patients receiving docetaxel. FKBP7 silencing showed that FKBP7 is required to maintain the growth of chemoresistant cell lines and chemoresistant tumors in mice. Mass spectrometry analysis revealed that FKBP7 interacts with eIF4G, a component of the eIF4F translation initiation complex, to mediate the survival of chemoresistant cells. Using small-molecule inhibitors of eIF4A, the RNA helicase component of eIF4F, we were able to kill docetaxel- and cabazitaxel-resistant cells. CONCLUSIONS Targeting FKBP7 or the eIF4G-containing eIF4F translation initiation complex could be novel therapeutic strategies to eradicate taxane-resistant prostate cancer cells.
Collapse
Affiliation(s)
- Marine F Garrido
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Nicolas J-P Martin
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Matthieu Bertrand
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Catherine Gaudin
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Frédéric Commo
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Nassif El Kalaany
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Nader Al Nakouzi
- Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Ladan Fazli
- Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Elaine Del Nery
- Institut Curie, PSL Research University, Paris, France.,Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France
| | - Jacques Camonis
- Institut Curie, PSL Research University, Paris, France.,Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.,INSERM, U830, Paris, France
| | - Franck Perez
- Institut Curie, PSL Research University, Paris, France.,Biophenics High-Content Screening Laboratory, Cell and Tissue Imaging Facility (PICT-IBiSA), Paris, France.,CNRS, UMR144, Paris, France
| | | | | | - Daniel Compagno
- Molecular and Functional Glyco-Oncology Lab, IQUIBICEN-CONICET, Facultad de Ciencias Exactas y Naturales-Universidad de Buenos Aires, CABA, Argentina
| | - Martin Gleave
- Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Yohann Loriot
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | | | - Stéphan Vagner
- Institut Curie, PSL Research University, Paris, France.,CNRS, UMR3348, Orsay, France
| | - Karim Fizazi
- Prostate Cancer Group, INSERM UMR981, Villejuif, France.,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| | - Anne Chauchereau
- Prostate Cancer Group, INSERM UMR981, Villejuif, France. .,Univ Paris-Sud, UMR981, Villejuif, France.,Gustave Roussy, Villejuif, France
| |
Collapse
|
6
|
Nakouzi NA, Wang CK, Nelepcu I, Crouzit C, Nabavi N, Almami A, Oo HZ, Clausen TM, Gustavsson T, Salanti A, Daugaard M. Abstract 5229: Expression and regulation of chondroitin sulfate in prostate cancer. Cancer Res 2018. [DOI: 10.1158/1538-7445.am2018-5229] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Increased levels of chondroitin sulfate (CS) glycosaminoglycans (GAGs) in prostate cancer (PC) have been observed for more than three decades. In 1984, De Klerk et al. noted that hyperplastic and cancerous prostate contained elevated levels of CS while other GAGs, like heparin sulfate (HS), were decreased. Chondroitin sulfate-modified proteoglycans (CSPGs), such as versican or tomoregulin (TENB2), have been promoted as PC progression markers. They have been associated with cell attachment to the matrix, the metastatic phenotype, disease progression, and androgen independence. Functionally, pericellular enrichment of CSPGs in the PC microenvironment promotes cell motility. Our team has discovered that human tumors display high levels of a specific highly sulfate type of CS normally restricted to placental and fetal tissue compartment. This "oncofetal" CS (ofCS) GAG can be conveniently detected and targeted using recombinant CS-binding VAR2CSA (rVAR2) lectins, derived from the malaria parasite Plasmodium falciparum. Recently, we identified chondroitin sulfate biosynthesis as being controlled by androgens in PC, modulating expression of the CHST11 and CHST13 carbon-4 GalNAc sulfotransferases. We established that these enzymes are under direct control of the androgen receptor (AR), regulating synthesis of the cancer-associated ofCS-modification on CSPGs. Glycosylation has a key role in many important biologic processes in cancer including cell differentiation. We identified CHST11 to be highly increased in high-risk neuroendocrine prostate cancer (NEPC) both in vitro, in vivo, and in situ. Moreover, cells that expressed neuroendocrine markers showed higher level of sulfation and ofCS. Our work reveals that alterations in GAG signatures regulated by AR might be responsible for progression neuroendocrine differentiation in prostate cancer. The prostate is an abundant secretor of PGs, and tumor-specific alterations in GAG signatures such as ofCS therefore constitute an untapped reservoir of potential biomarkers to be exploited as therapeutic targets.
Citation Format: Nader Al Nakouzi, Chris Kedong Wang, Irina Nelepcu, Coralie Crouzit, Noushin Nabavi, Amal Almami, Htoo Zarni Oo, Thomas Mandel Clausen, Tobias Gustavsson, Ali Salanti, Mads Daugaard. Expression and regulation of chondroitin sulfate in prostate cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5229.
Collapse
Affiliation(s)
- Nader Al Nakouzi
- 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Chris Kedong Wang
- 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Irina Nelepcu
- 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Coralie Crouzit
- 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Noushin Nabavi
- 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Amal Almami
- 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Htoo Zarni Oo
- 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| | - Thomas Mandel Clausen
- 2Centre for Medical Parasitology, Copenhagen University Hospital, Copenhagen, Denmark
| | - Tobias Gustavsson
- 2Centre for Medical Parasitology, Copenhagen University Hospital, Copenhagen, Denmark
| | - Ali Salanti
- 2Centre for Medical Parasitology, Copenhagen University Hospital, Copenhagen, Denmark
| | - Mads Daugaard
- 1Vancouver Prostate Centre, University of British Columbia, Vancouver, British Columbia, Canada
| |
Collapse
|
7
|
Li N, Truong S, Nouri M, Moore J, Al Nakouzi N, Lubik AA, Buttyan R. Non-canonical activation of hedgehog in prostate cancer cells mediated by the interaction of transcriptionally active androgen receptor proteins with Gli3. Oncogene 2018; 37:2313-2325. [PMID: 29429990 PMCID: PMC5916917 DOI: 10.1038/s41388-017-0098-7] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2017] [Revised: 10/18/2017] [Accepted: 11/29/2017] [Indexed: 12/11/2022]
Abstract
Hedgehog (Hh) is an oncogenic signaling pathway that regulates the activity of Gli transcription factors. Canonical Hh is a Smoothened- (Smo-) driven process that alters the post-translational processing of Gli2/Gli3 proteins. Though evidence supports a role for Gli action in prostate cancer (PCa) cell growth and progression, there is little indication that Smo is involved. Here we describe a non-canonical means for activation of Gli transcription in PCa cells mediated by the binding of transcriptionally-active androgen receptors (ARs) to Gli3. Androgens stimulated reporter expression from a Gli-dependent promoter in a variety of AR + PCa cells and this activity was suppressed by an anti-androgen, Enz, or by AR knockdown. Androgens also upregulated expression of endogenous Gli-dependent genes. This activity was associated with increased intranuclear binding of Gli3 to AR that was antagonized by Enz. Fine mapping of the AR binding domain on Gli2 showed that AR recognizes the Gli protein processing domain (PPD) in the C-terminus. Mutations in the arginine-/serine repeat elements of the Gli2 PPD involved in phosphorylation and ubiquitinylation blocked the binding to AR. β-TrCP, a ubiquitin ligase that recognizes the Gli PPD, competed with AR for binding to this site. AR binding to Gli3 suppressed its proteolytic processing to the Gli3 repressor form (Gli3R) whereas AR knockdown increased Gli3R. Both full-length and truncated ARs were able to activate Gli transcription. Finally, we found that an ARbinding decoy polypeptide derived from the Gli2 C-terminus can compete with Gli3 for binding to AR. Exogenous overexpression of this decoy suppressed Gli transcriptional activity in PCa cells. Collectively, this work identifies a novel pathway for non-canonical activation of Hh signaling in PCa cells and identifies a means for interference that may have clinical relevance for PCa patients.
Collapse
Affiliation(s)
- Na Li
- The Vancouver Prostate Centre, Vancouver, Canada
| | - Sarah Truong
- The Vancouver Prostate Centre, Vancouver, Canada.,The Interdisciplinary Oncology Program of The University of British Columbia, Vancouver, Canada
| | - Mannan Nouri
- The Interdisciplinary Oncology Program of The University of British Columbia, Vancouver, Canada
| | | | | | | | - Ralph Buttyan
- The Interdisciplinary Oncology Program of The University of British Columbia, Vancouver, Canada. .,Urologic Sciences, The University of British Columbia, Vancouver, Canada.
| |
Collapse
|
8
|
Peacock JW, Takeuchi A, Hayashi N, Liu L, Tam KJ, Al Nakouzi N, Khazamipour N, Tombe T, Dejima T, Lee KC, Shiota M, Thaper D, Lee WC, Hui DH, Kuruma H, Ivanova L, Yenki P, Jiao IZ, Khosravi S, Mui ALF, Fazli L, Zoubeidi A, Daugaard M, Gleave ME, Ong CJ. SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1. EMBO Mol Med 2018; 10:219-238. [PMID: 29348142 PMCID: PMC5801490 DOI: 10.15252/emmm.201707689] [Citation(s) in RCA: 45] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2017] [Revised: 11/22/2017] [Accepted: 12/01/2017] [Indexed: 02/06/2023] Open
Abstract
Growth factor receptor tyrosine kinase (RTK) pathway activation is a key mechanism for mediating cancer growth, survival, and treatment resistance. Cognate ligands play crucial roles in autocrine or paracrine stimulation of these RTK pathways. Here, we show SEMA3C drives activation of multiple RTKs including EGFR, ErbB2, and MET in a cognate ligand-independent manner via Plexin B1. SEMA3C expression levels increase in castration-resistant prostate cancer (CRPC), where it functions to promote cancer cell growth and resistance to androgen receptor pathway inhibition. SEMA3C inhibition delays CRPC and enzalutamide-resistant progression. Plexin B1 sema domain-containing:Fc fusion proteins suppress RTK signaling and cell growth and inhibit CRPC progression of LNCaP xenografts post-castration in vivo SEMA3C inhibition represents a novel therapeutic strategy for treatment of advanced prostate cancer.
Collapse
Affiliation(s)
- James W Peacock
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Ario Takeuchi
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urology, Graduate School of Medical Sciences Kyushi University, Fukuoka, Japan
| | - Norihiro Hayashi
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urology, The Jikei University School of Medicine, Tokyo, Japan
| | | | - Kevin J Tam
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | | | | | | | - Takashi Dejima
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urology, Graduate School of Medical Sciences Kyushi University, Fukuoka, Japan
| | - Kevin Ck Lee
- Vancouver Prostate Centre, Vancouver, BC, Canada
| | - Masaki Shiota
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urology, Graduate School of Medical Sciences Kyushi University, Fukuoka, Japan
| | - Daksh Thaper
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | | | | | | | | | - Parvin Yenki
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Ivy Zf Jiao
- Vancouver Prostate Centre, Vancouver, BC, Canada
| | | | - Alice L-F Mui
- Department of Surgery, University of British Columbia, Vancouver, BC, Canada
| | - Ladan Fazli
- Vancouver Prostate Centre, Vancouver, BC, Canada
| | - Amina Zoubeidi
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Mads Daugaard
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Martin E Gleave
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Christopher J Ong
- Vancouver Prostate Centre, Vancouver, BC, Canada
- Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
9
|
Lallous N, Leblanc E, Munuganti RSN, Hassona MDH, Nakouzi NA, Awrey S, Morin H, Roshan-Moniri M, Singh K, Lawn S, Yamazaki T, Adomat HH, Andre C, Daugaard M, Young RN, Guns EST, Rennie PS, Cherkasov A. Targeting Binding Function-3 of the Androgen Receptor Blocks Its Co-Chaperone Interactions, Nuclear Translocation, and Activation. Mol Cancer Ther 2016; 15:2936-2945. [PMID: 27765852 DOI: 10.1158/1535-7163.mct-16-0354] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2016] [Revised: 08/16/2016] [Accepted: 09/04/2016] [Indexed: 12/18/2022]
Abstract
The development of new antiandrogens, such as enzalutamide, or androgen synthesis inhibitors like abiraterone has improved patient outcomes in the treatment of advanced prostate cancer. However, due to the development of drug resistance and tumor cell survival, a majority of these patients progress to the refractory state of castration-resistant prostate cancer (CRPC). Thus, newer therapeutic agents and a better understanding of their mode of action are needed for treating these CRPC patients. We demonstrated previously that targeting the Binding Function 3 (BF3) pocket of the androgen receptor (AR) has great potential for treating patients with CRPC. Here, we explore the functional activity of this site by using an advanced BF3-specific small molecule (VPC-13566) that was previously reported to effectively inhibit AR transcriptional activity and to displace the BAG1L peptide from the BF3 pocket. We show that VPC-13566 inhibits the growth of various prostate cancer cell lines, including an enzalutamide-resistant cell line, and reduces the growth of AR-dependent prostate cancer xenograft tumors in mice. Importantly, we have used this AR-BF3 binder as a chemical probe and identified a co-chaperone, small glutamine-rich tetratricopeptide repeat (TPR)-containing protein alpha (SGTA), as an important AR-BF3 interacting partner. Furthermore, we used this AR-BF3-directed small molecule to demonstrate that inhibition of AR activity through the BF3 functionality can block translocation of the receptor into the nucleus. These findings suggest that targeting the BF3 site has potential clinical importance, especially in the treatment of CRPC and provide novel insights on the functional role of the BF3 pocket. Mol Cancer Ther; 15(12); 2936-45. ©2016 AACR.
Collapse
Affiliation(s)
- Nada Lallous
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Eric Leblanc
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Ravi S N Munuganti
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Mohamed D H Hassona
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Nader Al Nakouzi
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Shannon Awrey
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Helene Morin
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Mani Roshan-Moniri
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Kriti Singh
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Sam Lawn
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Takeshi Yamazaki
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Hans H Adomat
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Christophe Andre
- Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada
| | - Mads Daugaard
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Robert N Young
- Department of Chemistry, Simon Fraser University, Burnaby, BC, Canada
| | | | - Paul S Rennie
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada
| | - Artem Cherkasov
- Vancouver Prostate Centre, University of British Columbia, Vancouver, BC, Canada.
| |
Collapse
|
10
|
Clausen TM, Pereira MA, Al Nakouzi N, Oo HZ, Agerbæk MØ, Lee S, Ørum-Madsen MS, Kristensen AR, El-Naggar A, Grandgenett PM, Grem JL, Hollingsworth MA, Holst PJ, Theander T, Sorensen PH, Daugaard M, Salanti A. Oncofetal Chondroitin Sulfate Glycosaminoglycans Are Key Players in Integrin Signaling and Tumor Cell Motility. Mol Cancer Res 2016; 14:1288-1299. [PMID: 27655130 DOI: 10.1158/1541-7786.mcr-16-0103] [Citation(s) in RCA: 49] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2016] [Revised: 08/08/2016] [Accepted: 09/02/2016] [Indexed: 01/21/2023]
Abstract
Many tumors express proteoglycans modified with oncofetal chondroitin sulfate glycosaminoglycan chains (ofCS), which are normally restricted to the placenta. However, the role of ofCS in cancer is largely unknown. The function of ofCS in cancer was analyzed using the recombinant ofCS-binding VAR2CSA protein (rVAR2) derived from the malaria parasite, Plasmodium falciparum We demonstrate that ofCS plays a key role in tumor cell motility by affecting canonical integrin signaling pathways. Binding of rVAR2 to tumor cells inhibited the interaction of cells with extracellular matrix (ECM) components, which correlated with decreased phosphorylation of Src kinase. Moreover, rVAR2 binding decreased migration, invasion, and anchorage-independent growth of tumor cells in vitro Mass spectrometry of ofCS-modified proteoglycan complexes affinity purified from tumor cell lines on rVAR2 columns revealed an overrepresentation of proteins involved in cell motility and integrin signaling, such as integrin-β1 (ITGB1) and integrin-α4 (ITGA4). Saturating concentrations of rVAR2 inhibited downstream integrin signaling, which was mimicked by knockdown of the core chondroitin sulfate synthesis enzymes β-1,3-glucuronyltransferase 1 (B3GAT1) and chondroitin sulfate N-acetylgalactosaminyltransferase 1 (CSGALNACT1). The ofCS modification was highly expressed in both human and murine metastatic lesions in situ and preincubation or early intravenous treatment of tumor cells with rVAR2 inhibited seeding and spreading of tumor cells in mice. This was associated with a significant increase in survival of the animals. These data functionally link ofCS modifications with cancer cell motility and further highlights ofCS as a novel therapeutic cancer target. IMPLICATIONS The cancer-specific expression of ofCS aids in metastatic phenotypes and is a candidate target for therapy. Mol Cancer Res; 14(12); 1288-99. ©2016 AACR.
Collapse
Affiliation(s)
- Thomas Mandel Clausen
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark. .,Vancouver Prostate Centre, Vancouver, British Columbia, Canada.,Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.,Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Marina Ayres Pereira
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
| | - Nader Al Nakouzi
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada.,Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Htoo Zarni Oo
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada.,Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.,Molecular Pathology and Cell Imaging Laboratory, Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Mette Ø Agerbæk
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark.,Vancouver Prostate Centre, Vancouver, British Columbia, Canada.,Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Sherry Lee
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Maj Sofie Ørum-Madsen
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark.,Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Anders Riis Kristensen
- Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Amal El-Naggar
- Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Paul M Grandgenett
- Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska
| | - Jean L Grem
- Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska
| | - Michael A Hollingsworth
- Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, Nebraska
| | - Peter J Holst
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
| | - Thor Theander
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
| | - Poul H Sorensen
- Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, British Columbia, Canada
| | - Mads Daugaard
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada. .,Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.,Molecular Pathology and Cell Imaging Laboratory, Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Ali Salanti
- Centre for Medical Parasitology at Department of International Health, Immunology and Microbiology, University of Copenhagen, Denmark
| |
Collapse
|
11
|
Al Nakouzi N, Wang CK, Beraldi E, Jager W, Ettinger S, Fazli L, Nappi L, Bishop J, Zhang F, Chauchereau A, Loriot Y, Gleave M. Clusterin knockdown sensitizes prostate cancer cells to taxane by modulating mitosis. EMBO Mol Med 2016; 8:761-78. [PMID: 27198502 PMCID: PMC4931290 DOI: 10.15252/emmm.201506059] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Clusterin (CLU) is a stress‐activated molecular chaperone that confers treatment resistance to taxanes when highly expressed. While CLU inhibition potentiates activity of taxanes and other anti‐cancer therapies in preclinical models, progression to treatment‐resistant disease still occurs implicating additional compensatory survival mechanisms. Taxanes are believed to selectively target cells in mitosis, a complex mechanism controlled in part by balancing antagonistic roles of Cdc25C and Wee1 in mitosis progression. Our data indicate that CLU silencing induces a constitutive activation of Cdc25C, which delays mitotic exit and hence sensitizes cancer cells to mitotic‐targeting agents such as taxanes. Unchecked Cdc25C activation leads to mitotic catastrophe and cell death unless cells up‐regulate protective mechanisms mediated through the cell cycle regulators Wee1 and Cdk1. In this study, we show that CLU silencing induces a constitutive activation of Cdc25C via the phosphatase PP2A leading to relief of negative feedback inhibition and activation of Wee1‐Cdk1 to promote survival and limit therapeutic efficacy. Simultaneous inhibition of CLU‐regulated cell cycle effector Wee1 may improve synergistic responses of biologically rational combinatorial regimens using taxanes and CLU inhibitors.
Collapse
Affiliation(s)
- Nader Al Nakouzi
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Chris Kedong Wang
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Eliana Beraldi
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Wolfgang Jager
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Susan Ettinger
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Ladan Fazli
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Lucia Nappi
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Jennifer Bishop
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Fan Zhang
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| | - Anne Chauchereau
- Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France INSERM U981, Villejuif, France
| | - Yohann Loriot
- Department of Cancer Medicine, Gustave Roussy, Cancer Campus, Grand Paris, University of Paris-Sud, Villejuif, France INSERM U981, Villejuif, France
| | - Martin Gleave
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada
| |
Collapse
|
12
|
Todenhöfer T, Seiler R, Stewart C, Moskalev I, Gao J, Kamyabi A, Al Nakouzi N, Hayashi T, Choi S, Wang Y, Daugaard M, Frees S, Oo HZ, Hennenlotter J, Bedke J, Fazli L, Stenzl A, Black P. MP61-03 EVALUATION OF LACTATE TRANSPORTERS AS POTENTIAL THERAPEUTIC TARGET IN UROTHELIAL CARCINOMA. J Urol 2016. [DOI: 10.1016/j.juro.2016.02.877] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
13
|
Salanti A, Clausen TM, Agerbæk MØ, Al Nakouzi N, Dahlbäck M, Oo HZ, Lee S, Gustavsson T, Rich JR, Hedberg BJ, Mao Y, Barington L, Pereira MA, LoBello J, Endo M, Fazli L, Soden J, Wang CK, Sander AF, Dagil R, Thrane S, Holst PJ, Meng L, Favero F, Weiss GJ, Nielsen MA, Freeth J, Nielsen TO, Zaia J, Tran NL, Trent J, Babcook JS, Theander TG, Sorensen PH, Daugaard M. Targeting Human Cancer by a Glycosaminoglycan Binding Malaria Protein. Cancer Cell 2015; 28:500-514. [PMID: 26461094 PMCID: PMC4790448 DOI: 10.1016/j.ccell.2015.09.003] [Citation(s) in RCA: 139] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/12/2015] [Revised: 07/31/2015] [Accepted: 09/08/2015] [Indexed: 11/18/2022]
Abstract
Plasmodium falciparum engineer infected erythrocytes to present the malarial protein, VAR2CSA, which binds a distinct type chondroitin sulfate (CS) exclusively expressed in the placenta. Here, we show that the same CS modification is present on a high proportion of malignant cells and that it can be specifically targeted by recombinant VAR2CSA (rVAR2). In tumors, placental-like CS chains are linked to a limited repertoire of cancer-associated proteoglycans including CD44 and CSPG4. The rVAR2 protein localizes to tumors in vivo and rVAR2 fused to diphtheria toxin or conjugated to hemiasterlin compounds strongly inhibits in vivo tumor cell growth and metastasis. Our data demonstrate how an evolutionarily refined parasite-derived protein can be exploited to target a common, but complex, malignancy-associated glycosaminoglycan modification.
Collapse
Affiliation(s)
- Ali Salanti
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark.
| | - Thomas M Clausen
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada; Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada
| | - Mette Ø Agerbæk
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark; Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada
| | - Nader Al Nakouzi
- Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada
| | - Madeleine Dahlbäck
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Htoo Zarni Oo
- Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada
| | - Sherry Lee
- Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
| | - Tobias Gustavsson
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Jamie R Rich
- Kairos Therapeutics, Inc., Vancouver, BC V6T 1Z3, Canada; Centre for Drug Research and Development, Vancouver, BC V6T 1Z3, Canada
| | - Bradley J Hedberg
- Kairos Therapeutics, Inc., Vancouver, BC V6T 1Z3, Canada; Centre for Drug Research and Development, Vancouver, BC V6T 1Z3, Canada
| | - Yang Mao
- Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA
| | - Line Barington
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Marina A Pereira
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Janine LoBello
- Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA
| | - Makoto Endo
- Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC V6H 3Z6, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada; Department of Anatomic Pathology, Kyushu University, Fukuoka 812-8582, Japan; Department of Orthopaedic Surgery, Kyushu University, Fukuoka 819-0395, Japan
| | - Ladan Fazli
- Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
| | - Jo Soden
- Retrogenix Ltd., Crown House, Bingswood Estate, Whaley Bridge, High Peak SK23 7LY, UK
| | - Chris K Wang
- Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada
| | - Adam F Sander
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Robert Dagil
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Susan Thrane
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Peter J Holst
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Le Meng
- Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA
| | - Francesco Favero
- Centre for Biological Sequence Analysis, Technical University of Denmark, Lyngby 2800, Denmark
| | - Glen J Weiss
- Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA; Cancer Treatment Centers of America, Goodyear, AZ 85338, USA
| | - Morten A Nielsen
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Jim Freeth
- Retrogenix Ltd., Crown House, Bingswood Estate, Whaley Bridge, High Peak SK23 7LY, UK
| | - Torsten O Nielsen
- Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, BC V6H 3Z6, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC V6T 2B5, Canada
| | - Joseph Zaia
- Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118, USA
| | - Nhan L Tran
- Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA
| | - Jeff Trent
- Translational Genomics Research Institute (TGen), Phoenix, AZ 85004, USA
| | - John S Babcook
- Kairos Therapeutics, Inc., Vancouver, BC V6T 1Z3, Canada; Centre for Drug Research and Development, Vancouver, BC V6T 1Z3, Canada
| | - Thor G Theander
- Department of Immunology and Microbiology, Centre for Medical Parasitology, University of Copenhagen, 1014 Copenhagen, Denmark; Department of Infectious Diseases, Copenhagen University Hospital, 2100 Copenhagen, Denmark
| | - Poul H Sorensen
- Department of Molecular Oncology, British Columbia Cancer Research Centre, Vancouver, BC V5Z 1L3, Canada
| | - Mads Daugaard
- Vancouver Prostate Centre, Vancouver, BC V6H 3Z6, Canada; Department of Urologic Sciences, University of British Columbia, Vancouver, BC V5Z 1M9, Canada.
| |
Collapse
|
14
|
Yamamoto Y, Loriot Y, Beraldi E, Zhang F, Wyatt AW, Al Nakouzi N, Mo F, Zhou T, Kim Y, Monia BP, MacLeod AR, Fazli L, Wang Y, Collins CC, Zoubeidi A, Gleave M. Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth. Clin Cancer Res 2015; 21:1675-87. [PMID: 25634993 DOI: 10.1158/1078-0432.ccr-14-1108] [Citation(s) in RCA: 94] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2014] [Accepted: 01/08/2015] [Indexed: 11/16/2022]
Abstract
PURPOSE Enzalutamide (ENZ) is a potent androgen receptor (AR) antagonist with activity in castration-resistant prostate cancer (CRPC); however, progression to ENZ-resistant (ENZ-R) CRPC frequently occurs with rising serum PSA levels, implicating AR full-length (ARFL) or variants (AR-Vs) in disease progression. EXPERIMENTAL DESIGN To define functional roles of ARFL and AR-Vs in ENZ-R CRPC, we designed 3 antisense oligonucleotides (ASO) targeting exon-1, intron-1, and exon-8 in AR pre-mRNA to knockdown ARFL alone or with AR-Vs, and examined their effects in three CRPC cell lines and patient-derived xenografts. RESULTS ENZ-R-LNCaP cells express high levels of both ARFL and AR-V7 compared with CRPC-LNCaP; in particular, ARFL levels were approximately 12-fold higher than AR-V7. Both ARFL and AR-V7 are highly expressed in the nuclear fractions of ENZ-R-LNCaP cells even in the absence of exogenous androgens. In ENZ-R-LNCaP cells, knockdown of ARFL alone, or ARFL plus AR-Vs, similarly induced apoptosis, suppressed cell growth and AR-regulated gene expression, and delayed tumor growth in vivo. In 22Rv1 cells that are inherently ENZ-resistant, knockdown of both ARFL and AR-Vs more potently suppressed cell growth, AR transcriptional activity, and AR-regulated gene expression than knockdown of ARFL alone. Exon-1 AR-ASO also inhibited tumor growth of LTL-313BR patient-derived CRPC xenografts. CONCLUSIONS These data identify the AR as an important driver of ENZ resistance, and while the contributions of ARFL and AR-Vs can vary across cell systems, ARFL is the key driver in the ENZ-R LNCaP model. AR targeting strategies against both ARFL and AR-Vs is a rational approach for AR-dependent CRPC.
Collapse
Affiliation(s)
- Yoshiaki Yamamoto
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada. Department of Urology, Graduate School of Medicine, Yamaguchi University, Ube, Japan
| | - Yohann Loriot
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Eliana Beraldi
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Fan Zhang
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Alexander W Wyatt
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Nader Al Nakouzi
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Fan Mo
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Tianyuan Zhou
- Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California
| | - Youngsoo Kim
- Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California
| | - Brett P Monia
- Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California
| | - A Robert MacLeod
- Department of Antisense Drug Discovery, Isis Pharmaceuticals Inc., Carlsbad, California
| | - Ladan Fazli
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Yuzhuo Wang
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Colin C Collins
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Amina Zoubeidi
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada
| | - Martin Gleave
- The Vancouver Prostate Centre and Department of Urologic Sciences, University of British Columbia, Vancouver, British Columbia, Canada.
| |
Collapse
|
15
|
Al Nakouzi N, Cotteret S, Commo F, Gaudin C, Rajpar S, Dessen P, Vielh P, Fizazi K, Chauchereau A. Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer. Oncotarget 2014; 5:667-78. [PMID: 24525428 PMCID: PMC3996665 DOI: 10.18632/oncotarget.1574] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2013] [Accepted: 01/06/2014] [Indexed: 11/25/2022] Open
Abstract
Docetaxel is used as a standard treatment in patients with metastatic castration-resistant prostate cancer. However, a large subset of patients develops resistance. Understanding resistance mechanisms, which are largely unknown, will allow identification of predictive biomarkers and therapeutic targets. We established resistant IGR-CaP1 prostate cancer cell lines for different doses of Docetaxel. We investigated gene expression profiles by microarray analyses in these cell lines and generated a signature of 99 highly differentially expressed genes potentially implicated in chemoresistance. We focused on the role of the cell cycle regulator LZTS1, which was under-expressed in the Docetaxel-resistant cell lines, its inhibition resulting from the promoter methylation. Knockdown of LZTS1 in parental cells with siRNA showed that LZTS1 plays a role in the acquisition of the resistant phenotype. Furthermore, we observed that targeting CDC25C, a partner of LZTS1, with the NSC663284 inhibitor specifically killed the Docetaxel-resistant cells. To further investigate the role of CDC25C, we used inhibitors of the mitotic kinases that regulate CDC25C. Inhibition of CHEK1 and PLK1 induced growth arrest and cell death in the resistant cells. Our findings identify an important role of LZTS1 through its regulation of CDC25C in Docetaxel resistance in prostate cancer and suggest that CDC25C, or the mitotic kinases CHEK1 and PLK1, could be efficient therapeutic targets to overcome Docetaxel resistance.
Collapse
Affiliation(s)
- Nader Al Nakouzi
- Prostate Cancer Group, INSERM U981, Gustave Roussy, Villejuif, F-94805, France
- INSERM U981, LabEx LERMIT, Gustave Roussy
- University Paris-Sud 11, France
| | - Sophie Cotteret
- Prostate Cancer Group, INSERM U981, Gustave Roussy, Villejuif, F-94805, France
- INSERM U981, LabEx LERMIT, Gustave Roussy
- University Paris-Sud 11, France
| | - Frédéric Commo
- INSERM U981, LabEx LERMIT, Gustave Roussy
- University Paris-Sud 11, France
| | - Catherine Gaudin
- Prostate Cancer Group, INSERM U981, Gustave Roussy, Villejuif, F-94805, France
- INSERM U981, LabEx LERMIT, Gustave Roussy
- University Paris-Sud 11, France
| | - Shanna Rajpar
- Prostate Cancer Group, INSERM U981, Gustave Roussy, Villejuif, F-94805, France
- INSERM U981, LabEx LERMIT, Gustave Roussy
- University Paris-Sud 11, France
| | | | - Philippe Vielh
- INSERM U981, LabEx LERMIT, Gustave Roussy
- Department of Pathology, HistoCytoPathology Unit, Translational Research Laboratory and Biobank, Gustave Roussy
- University Paris-Sud 11, France
| | - Karim Fizazi
- Prostate Cancer Group, INSERM U981, Gustave Roussy, Villejuif, F-94805, France
- INSERM U981, LabEx LERMIT, Gustave Roussy
- Department of Medicine, Gustave Roussy
- University Paris-Sud 11, France
| | - Anne Chauchereau
- Prostate Cancer Group, INSERM U981, Gustave Roussy, Villejuif, F-94805, France
- INSERM U981, LabEx LERMIT, Gustave Roussy
- University Paris-Sud 11, France
| |
Collapse
|
16
|
Al Nakouzi N, Beraldi E, Shepherd S, Loriot Y, Kim S, Leichmann L, Zoubeidi A, Gleave ME. Abstract 4062: Clusterin downregulation sensitize prostate cancer cells to taxane by modulating mitosis. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-4062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Clusterin (CLU) is a stress-activated molecular chaperone closely linked to treatment resistance and cancer progression. CLU is a novel therapeutic anti-cancer target with both preclinical and phase II clinical proof of concept using the antisense OGX-011 inhibitor; phase III clinical trials of combination docetaxel + OGX-011 are underway.
Cytotoxic chemotherapy drugs like taxane are believed to gain selectivity by targeting cells that are in mitosis. When cultured cancer cells are treated with taxane, only cells that enter mitosis are killed or rendered senescent. Quiescent cells or cycling cells that do not reach mitosis during drug exposure are spared. In this sense, sentisizing cells to taxane can occur through mitosis regulation.
In this study, we show that CLU downregulation enhances cytotoxicity of the new generation taxane cabazitaxol. Treatment of PC3 human prostate cancer cells with cabazitaxol induces G2/M arrest followed by mitotic death. Downregulation of CLU accelerated these G2/M associated events and resulted in reduced cabazitaxol EC50 and clonogenic survival upon cabazitaxol treatment. To investigate the mechanisms that allow CLU deficient cells to respond to taxane and examine whether this response is linked to a role of CLU in the control of cell cycle progression, we knocked down CLU expression in PC3 and LNCaP cells and found an accumulation of cells in G2/M phase and a reduction in cell growth. The screening of different cell cycle effectors after CLU downregulation in different cell lines and xenografts shows that CLU specifically regulates Cdc25C, while the two other Cdc25 isoforms, A and B, are not affected. Interestingly Cdc25C is a key regulator of mitosis initiation and exit. Importantly, we show that Cdc25C and CLU expression negatively correlate in prostate cancer cell lines, xenografts and human biopsies. When CLU is down regulated, Cdc25C transcription increased resulting in protein accumulation; as a consequence, cells showed G2/M blockage and slower mitotic progression. Accordingly, we suggest that down regulation of CLU alters sensitivity to taxane by modulating exit from mitosis, which is controlled by Cdc25C.
Citation Format: Nader Al Nakouzi, Eliana Beraldi, Stuart Shepherd, Yohann Loriot, Soojin Kim, Lauren Leichmann, Amina Zoubeidi, Martin E Gleave. Clusterin downregulation sensitize prostate cancer cells to taxane by modulating mitosis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 4062. doi:10.1158/1538-7445.AM2013-4062
Collapse
Affiliation(s)
- Nader Al Nakouzi
- Vancouver Prostate Centre/UBC, Vancouver, British Columbia, Canada
| | - Eliana Beraldi
- Vancouver Prostate Centre/UBC, Vancouver, British Columbia, Canada
| | - Stuart Shepherd
- Vancouver Prostate Centre/UBC, Vancouver, British Columbia, Canada
| | - Yohann Loriot
- Vancouver Prostate Centre/UBC, Vancouver, British Columbia, Canada
| | - Soojin Kim
- Vancouver Prostate Centre/UBC, Vancouver, British Columbia, Canada
| | - Lauren Leichmann
- Vancouver Prostate Centre/UBC, Vancouver, British Columbia, Canada
| | - Amina Zoubeidi
- Vancouver Prostate Centre/UBC, Vancouver, British Columbia, Canada
| | - Martin E Gleave
- Vancouver Prostate Centre/UBC, Vancouver, British Columbia, Canada
| |
Collapse
|
17
|
Cotteret S, Al Nakouzi N, Gaudin C, Commo F, Rajpar S, Lejuste S, Martin N, Fizazi K, Chauchereau A. Abstract 956: Role of the cell cycle regulator LZTS1 in docetaxel resistance of prostate cancer cells and overcoming the docetaxel resistance by cell cycle pharmacological inhibitors. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-956] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Docetaxel is the standard treatment for metastatic castration-resistant prostate cancer (CRPC) since 2004 and overall survival benefit in CRPC has been demonstrated in docetaxel-treated patients. In spite of this benefit, a drug resistance is eventually observed in all patients, leaving few therapeutic options. Therefore, it is crucial to identify predictive markers that enable selection of patients who will respond to treatment.
Methods: Three docetaxel-resistant prostate cancer cell lines (LNCaP, PC3 and IGR-CaP1) were obtained by continuous exposure to Docetaxel. A high-density genomic profiling by cDNA microarrays (Agilent technologies) was performed to compare sensitive and chemoresistant cell lines and a signature of 99 highly differentially expressed genes (with Fold Change >5) potentially implicated in chemoresistance was generated.
Results: We focused on the role of the cell cycle regulator LZTS1, which was strongly under-expressed in all the docetaxel-resistant cell lines. This underexpression was due to a stretch of 20 highly methylated CpGs in the region encompassing the exon 1 of the LZTS1 promoter in resistant cells. Knockdown of LZTS1 in IGR-CaP1 parental cells with siRNA showed that LZTS1 plays an important role in the acquisition of the resistant phenotype. Importantly, immunohistochemical staining showed a loss of LZTS1 expression in 33% of diagnostic biopsies obtained from patients with metastatic CRPC. Furthermore, we observed that targeting Cdc25C, a partner of LZTS1, with the Cdc25 pharmacological inhibitor NSC 663284 killed specifically the docetaxel-resistant cells. There are currently no CDC25C inhibitors tested in clinical trials, therefore we are currently investigating the role of other kinases that are involved in the G2/M checkpoint and in the regulation of CDC25C. Importantly, inhibitors of these kinases are currently being assessed in clinical trials. We wish to determine if targeting CDC25C and/or other kinases could kill docetaxel-resistant cells and if the use of such inhibitors could be a promising strategy to overcome docetaxel resistance in prostate cancer.
Conclusion: High-density microarray genomic analyses comparing chemo-resistant versus sensitive prostate cancer cell lines were used to identify signatures of genes and microRNAs, and signaling pathways potentially implicated in Docetaxel resistance.
Our findings identify an important role of LZTS1 in docetaxel resistance in prostate cancer through its regulation of CDC25C. It could also provide the framework for formulation of novel combined therapies that may improve taxane therapy efficacy or prevent chemoresistance in men with prostate cancer.
Citation Format: Sophie Cotteret, Nader Al Nakouzi, Catherine Gaudin, Frederic Commo, Shanna Rajpar, Sandra Lejuste, Nicolas Martin, Karim Fizazi, Anne Chauchereau. Role of the cell cycle regulator LZTS1 in docetaxel resistance of prostate cancer cells and overcoming the docetaxel resistance by cell cycle pharmacological inhibitors. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 956. doi:10.1158/1538-7445.AM2013-956
Collapse
Affiliation(s)
- Sophie Cotteret
- INSERM U981 - Institut Gustave Roussy, Villejuif Cedex, France
| | | | | | - Frederic Commo
- INSERM U981 - Institut Gustave Roussy, Villejuif Cedex, France
| | - Shanna Rajpar
- INSERM U981 - Institut Gustave Roussy, Villejuif Cedex, France
| | - Sandra Lejuste
- INSERM U981 - Institut Gustave Roussy, Villejuif Cedex, France
| | - Nicolas Martin
- INSERM U981 - Institut Gustave Roussy, Villejuif Cedex, France
| | - Karim Fizazi
- INSERM U981 - Institut Gustave Roussy, Villejuif Cedex, France
| | | |
Collapse
|
18
|
Loriot Y, Wyatt A, Al Nakouzi N, Beraldi E, Toren P, Nip KM, Gleave M, Zoubeidi A. Abstract 3386: Mechanisms of resistance to enzalutamide in LNCaP models. Cancer Res 2013. [DOI: 10.1158/1538-7445.am2013-3386] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background
MDV3100 is a potent androgen receptor (AR) antagonist with activity in castration resistant prostate cancer (CRPC); however, progression to MDV3100-resistant (MDV-R) CRPC frequently occurs with rising serum PSA levels suggesting reactivation of AR pathway. We sought to identify AR-based mechanisms of resistance.
Methods
We treated human CRPC LNCAP-derived xenografts with MDV3100 and assessed androgen receptor (AR) levels and localization as well as genomic alterations versus controls. We also generated by selection MDV3100-R LNCaP-derived sub-lines to study mechanisms of resistance to MDV3100.
Results
Serum and tumoral PSA levels were consistently increased in resistant xenogratfs as compared with sensitive xenografts along with AR nuclear localization. MDV3100 did not induce any new mutation in the DNA binding domain and any AR DNA gene amplification. AR full-length (ARfl) and AR-V7 splicing variant were both highly expressed in RNA sequencing compared to CRPC LNCaP xenografts. However, it was no enrichment of AR-V7 versus ARfl in LNCaP MDV-R xenografts. Interestingly, AR was found in the nucleus and constitutively binding to DNA on androgen response element on PSA enhancer as measured by Chromatin immunoprecipitation in MDV-R cell lines compared to CRPC cell lines. These data were translated by increase of AR responsive genes at both mRNA and protein levels.
Conclusions
MDV-R LNCaP cells exhibited AR overexpression without any significant genomic alterations. While MDV3100 induces both ARfl and AR-V7 levels, no enrichment of AR-V7 was detected. Immunofluorescence, CHIP and qPCR studies suggest that ARfl overexpression remains a significant mechanism of resistance to MDV3100 similar to resistance from chronic androgen depletion.
Citation Format: Yohann Loriot, Alexander Wyatt, Nader Al Nakouzi, Eliana Beraldi, Paul Toren, Ka Mun Nip, Martin Gleave, Amina Zoubeidi. Mechanisms of resistance to enzalutamide in LNCaP models. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 3386. doi:10.1158/1538-7445.AM2013-3386
Note: This abstract was not presented at the AACR Annual Meeting 2013 because the presenter was unable to attend.
Collapse
Affiliation(s)
- Yohann Loriot
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Alexander Wyatt
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | | | - Eliana Beraldi
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Paul Toren
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Ka Mun Nip
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Martin Gleave
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| | - Amina Zoubeidi
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada
| |
Collapse
|
19
|
Laderach DJ, Gentilini LD, Giribaldi L, Delgado VC, Nugnes L, Croci DO, Al Nakouzi N, Sacca P, Casas G, Mazza O, Shipp MA, Vazquez E, Chauchereau A, Kutok JL, Rodig SJ, Elola MT, Compagno D, Rabinovich GA. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 2012; 73:86-96. [PMID: 23108139 DOI: 10.1158/0008-5472.can-12-1260] [Citation(s) in RCA: 125] [Impact Index Per Article: 10.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023]
Abstract
Galectins, a family of glycan-binding proteins, influence tumor progression by modulating interactions between tumor, endothelial, stromal, and immune cells. Despite considerable progress in identifying the roles of individual galectins in tumor biology, an integrated portrait of the galectin network in different tumor microenvironments is still missing. We undertook this study to analyze the "galectin signature" of the human prostate cancer microenvironment with the overarching goal of selecting novel-molecular targets for prognostic and therapeutic purposes. In examining androgen-responsive and castration-resistant prostate cancer cells and primary tumors representing different stages of the disease, we found that galectin-1 (Gal-1) was the most abundantly expressed galectin in prostate cancer tissue and was markedly upregulated during disease progression. In contrast, all other galectins were expressed at lower levels: Gal-3, -4, -9, and -12 were downregulated during disease evolution, whereas expression of Gal-8 was unchanged. Given the prominent regulation of Gal-1 during prostate cancer progression and its predominant localization at the tumor-vascular interface, we analyzed the potential role of this endogenous lectin in prostate cancer angiogenesis. In human prostate cancer tissue arrays, Gal-1 expression correlated with the presence of blood vessels, particularly in advanced stages of the disease. Silencing Gal-1 in prostate cancer cells reduced tumor vascularization without altering expression of other angiogenesis-related genes. Collectively, our findings identify a dynamically regulated "galectin-specific signature" that accompanies disease evolution in prostate cancer, and they highlight a major role for Gal-1 as a tractable target for antiangiogenic therapy in advanced stages of the disease.
Collapse
Affiliation(s)
- Diego J Laderach
- Laboratorio de Glicómica Estructural y Funcional, IQUIBICEN-CONICET, Departamento de Química Biológica, Facultad de Ciencias Exactas y Naturales, Universidad de Buenos Aires, Buenos Aires, Argentina.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Martin N, Aarab-Terrisse S, Commo F, Nakouzi NA, Gaudin C, Lejuste S, Cotteret S, Massard C, Fizazi K, Chauchereau A. Abstract 823: Integration of microRNA and gene expression signatures from several models of Docetaxel-resistant prostate cancer cell lines. Cancer Res 2012. [DOI: 10.1158/1538-7445.am2012-823] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Docetaxel is the standard treatment for metastatic castration-resistant prostate cancer (CRPC) since 2004 and overall survival benefit in CRPC has been demonstrated in docetaxel-treated patients. In spite of this benefit, a drug resistance is eventually observed in all patients, leaving few therapeutic options. Therefore, it is crucial to identify predictive markers that enable selection of patients who will respond to treatment. Methods: Three docetaxel-resistant prostate cancer cell lines (LNCaP, PC3 and IGR-CaP1) were obtained by continuous exposure to Docetaxel. A high-density genomic profiling by cDNA microarrays (Agilent technologies) was performed to compare sensitive and chemoresistant cell lines. The differential expression levels of 377 microRNAs between resistant and sensitive parental cell lines were measured by Taqman Low Density Array (TLDA, Applied Biosystems technology). Each determination was generated from biological replicates in the absence of drug. Results: A gene expression signature of 583 genes was generated by the bootstrap method (Fold change>2 for each doses of Docetaxel, P value <10-5) in IGR-CaP1 cells. Based on the hypothesis of a biological effect due to increasing drug, a second microarray expression profile was identified using a 5-parameters logistic regression model. This analysis led to the identification of 486 genes associated with resistance to increasing doses of docetaxel (with a P value ≤ 10-5 and a fold change between the first and the last dose of drug ≤ 2). 45 genes were common in the two analyses. A 65 miRs expression profile of docetaxel resistance was determined in all three cell lines using two reference miRs. Interestingly, we identified the under-expression of three clusters of miRs in the resistant cells. In particular, the under-expression of the miR 141-200c cluster was inversely correlated to the over-expression of its target genes Jagged1 (JAG1) and dll1(DLL1), which were identified in the gene expression signature. JAG1 and DLL1 are ligands for Notch receptors, thus we are currently exploring the role of the miR-200c/ZEB1/JAG1 axis and the Notch signalling pathway in mechanisms of Docetaxel resistance. Conclusion: High-density microarray genomic and microRNA profiling analyses comparing chemo-resistant versus sensitive prostate cancer cell lines were used to identify signatures of genes and microRNAs, and signaling pathways potentially implicated in Docetaxel resistance. Ultimately, integration of data from gene and microRNA expression will allow the identification of biomarkers to select patients that could benefit from Docetaxel chemotherapy. It could also provide the framework for formulation of novel therapies that may improve taxane therapy efficacy in men with prostate cancer.
Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 823. doi:1538-7445.AM2012-823
Collapse
Affiliation(s)
- Nicolas Martin
- 1INSERM Unit 981, Institut Gustave Roussy, Villejuif, France
| | | | | | | | | | - Sandra Lejuste
- 1INSERM Unit 981, Institut Gustave Roussy, Villejuif, France
| | - Sophie Cotteret
- 1INSERM Unit 981, Institut Gustave Roussy, Villejuif, France
| | | | - Karim Fizazi
- 1INSERM Unit 981, Institut Gustave Roussy, Villejuif, France
| | | |
Collapse
|
21
|
Chauchereau A, Al Nakouzi N, Gaudin C, Le Moulec S, Compagno D, Auger N, Bénard J, Opolon P, Rozet F, Validire P, Fromont G, Fizazi K. Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer. Exp Cell Res 2010; 317:262-75. [PMID: 20974126 DOI: 10.1016/j.yexcr.2010.10.012] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2010] [Revised: 09/20/2010] [Accepted: 10/16/2010] [Indexed: 01/06/2023]
Abstract
Deciphering molecular pathways involved in the early steps of prostate oncogenesis requires both in vitro and in vivo models derived from human primary tumors. However the few recognized models of human prostate epithelial cancer originate from metastases. To date, very few models are proposed from primary tumors and immortalizing normal human prostate cells does not recapitulate the natural history of the disease. By culturing human prostate primary tumor cells onto human epithelial extra-cellular matrix, we successfully selected a new prostate cancer cell line, IGR-CaP1, and clonally-derived subclones. IGR-CaP1 cells, that harbor a tetraploid karyotype, high telomerase activity and mutated TP53, rapidly induced subcutaneous xenografts in nude mice. Furthermore, IGR-CaP1 cell lines, all exhibiting negativity for the androgen receptor and PSA, express the specific prostate markers alpha-methylacyl-CoA racemase and a low level of the prostate-specific membrane antigen PSMA, along with the prostate basal epithelial markers CK5 and CK14. More importantly, these clones express high CD44, CD133, and CXCR4 levels associated with high expression of α2β1-integrin and Oct4 which are reported to be prostate cancer stemness markers. RT-PCR data also revealed high activation of the Sonic Hedgehog signalling pathway in these cells. Additionally, the IGR-CaP1 cells possess a 3D sphere-forming ability and a renewal capacity by maintaining their CSC potential after xenografting in mice. As a result, the hormone-independent IGR-CaP1 cellular clones exhibit the original features of both basal prostate tissue and cancer stemness. Tumorigenic IGR-CaP1 clones constitute invaluable human models for studying prostate cancer progression and drug assessment in vitro as well as in animals specifically for developing new therapeutic approaches targeting prostate cancer stem cells.
Collapse
Affiliation(s)
- Anne Chauchereau
- Prostate Cancer Group, INSERM U981, Institut Gustave Roussy, Villejuif F-94805, France.
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|